explore -WSS

explore

author：Wikipedia 2025-10-02 12:02:13 - browse：36

Photograph of an abandoned lab with empty bottle, boxes, and beakers all around. -- biotech coverage from STAT — Adobe

SAN DIEGO — It was spring 2020, and Histogen, a small biotech with big ambitions to regenerate tissues throughout the body and turn a profit in the process, had just gone public. The company’s leadership believed they were poised for success — until everything slowly and irreversibly fell apart.

Three years later, Histogen no longer develops therapies. It has abandoned efforts to reverse baldness, replenish cartilage in achy knees, and quell infection and inflammation.

The company has no lab. It has no headquarters. It has just two employees, including a chief financial officer who also serves as secretary, CEO, and president. Histogen’s stock trades below $1 a share. And even that is coming to a close. On Thursday, the Nasdaq suspended trading of Histogen shares after determining that the company’s operations and assets are negligible, meaning the biotech is now officially a shell of its former self.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： CRISPR pioneers react to Casgevy, first gene

WSS

Childhood cancer progress stalls for Black, Hispanic kids: Report

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

‘Oppenheimer’ and the risks of AI in health care

Amazon expands telehealth clinic nationwide

NYU radiologists take on the challenge of expensive MRI machines

entertainment

explore

knowledge

Supreme Court strikes down use of affirmative action

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

State Dept. review finds Biden bears some blame for Afghanistan failures

Surge of respiratory disease in China has likely explanation

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The high personal cost of affirmative action for Black doctors

Moonlake's readout produced a cash windfall. Risks remain

Mitch McConnell episode has important public health takeaway

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

focus

Hospitals look to new technology to keep health care workers safe

Anthos stroke drug appears safer than common blood thinner

Weight loss drug costs may need more research, senator suggests

Adults seen as increasingly susceptible to measles

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Weight loss drug costs may need more research, senator suggests

explore

hotspot

hotspot

focus